Recent successes of Capstan and Verve on LNP safety have put the industry back in the spotlight and reignited hope that lipid nanoparticles can overcome the biggest hurdles in drug delivery. However, Intellia’s pause to its CRISPR trial following an FDA request for additional safety data serves as a reminder of how crucial it is to deepen our understanding of immunogenicity and toxicity in LNP delivery.

The 4th LNP Immunogenicity & Toxicity Summit returns this December as a forum to stay ahead of emerging safety insights, benchmark pre-clinical and clinical strategies, and ensure your LNP programs are built for regulatory confidence and clinical success.

This year’s unmissable one-day virtual summit will bring you the latest breakthroughs and real-world insights driving safer, smarter LNP development. Dive deep into cutting-edge discussions spanning predictive and AI modelling, translational animal models, and PK/PD strategies designed to accelerate prediction, optimize dosing, and boost the clinical performance of pegylated and ionizable LNPs across all payloads.

From headline sessions tackling the translational gap between preclinical and clinical findings, the next frontier in extrahepatic delivery, to regulatory guidance shaping the future of LNP approvals, and repeat dosing and PEGylation challenges that every program must overcome, this is a conversation not to miss.

Log on to the platform from the comfort of your home or office and connect with 60+ leading LNP experts in immunology, toxicology, pharmacology, and bioanalytics, all from the comfort of your home or office, to learn, collaborate, and connect with the brightest minds advancing the next generation of safe and effective LNPs.

View the event here.